DEC 07, 2016 09:00 AM PST
The Interplay of Kinase Broad Profiling and Phenotypic Screening
SPONSORED BY: DiscoverX
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
4 5 799

Speakers:
  • Senior Principal Scientist in Computational Chemistry, Janssen Research & Development
    Biography
      Edgar Jacoby holds a Licence en Sciences Chimiques from Louvain and a Dr.rer.nat. in Computational Chemistry from the RWTH Aachen. After post-doctoral work in Molecular Biophysics at Harvard Medical School and The University of Chicago, he joined Servier in 1995 as Cadre de Recherches in Molecular Modeling. In 1999, he joined the Combinatorial Chemistry group at Novartis Central Technologies as Lab Head for the in silico design of combinatorial compound libraries. From 2002-2012 he led the Molecular and Library Informatics group in the Novartis Center of Proteomic Chemistry in Basel. In 2013, he joined Janssen Research & Development in Beerse as Senior Principal Scientist in Computational Chemistry.

    Abstract:
    DATE: December 7, 2016
    TIME: 9:00 AM PT, 12:00 PM ET


    Kinases play important roles in many biological signaling pathways. Kinase inhibitors are therefore potentially found as actives in typical phenotypic screens. In this webinar, we provide detail on the design of the Janssen kinase inhibitor broad profiling project and its impact on general early kinase drug discovery projects.  For two selected examples, the mouse embryonic stem cell stemness assay, run in collaboration with Dundee DSTT, and the literature reported splicing corrector assay of pre-Lamin A, we show how kinase inhibitor broad profiling and chem-bioinformatic analyses developed in the IMI OpenPhacts consortium can impact target deconvolution after phenotypic screening. The outcomes of these analyses are lists of potential kinase targets for further biological validation.

    Learning Objective 1: Learn about the significance of kinase broad profiling and phenotypic screening on early kinase drug discovery

    Learning Objective 2: Learn how to design a kinase inhibitor broad profiling project and how the chemo-bioinformatic analysis can impact target deconvolution after phenotypic screening

    Show Resources
    Loading Comments...